A randomized trial of children and adolescents with major depressive disorder reported the efficacy of fluoxetine, but determined that sertraline and citalopram did not outweigh the risks. In addition, the effectiveness of tricyclic antidepressants and other SSRIs and SNRIs has not been proven.
Contraindications to paroxetine for patients with major depressive disorder under the age of 18 have led to discussions involving national regulators and experts, but other antidepressants are also being considered.
It has been revealed that all SSRIs, SNRIs and tricyclic antidepressants are at risk of inducing suicide related events in children, adolescents and young adults under the age of 24.
In addition, suicide-related events are likely to occur at the beginning of administration and when the dose is increased or decreased, anxiety, agitation, insomnia, irritability, impulsivity, akathisia, etc., and withdrawal symptoms occur when the drug is administered.
Discontinued. It has been warned that gradual discontinuation is necessary because it develops. If antidepressants do not respond to major depressive disorders in children and adolescents, additional doses of lithium, bupropion, new antipsychotics, etc. are recommended, but there is little evidence to support this.
On the other hand, in addition to the effectiveness of psychotherapy, such as cognitive-behavioral therapy and interpersonal psychotherapy, it has been shown that the therapeutic effect is enhanced by the combination of cognitive-behavioral therapy and drug therapy. Keywords: antidepressant, major depressive disorder, suicidal behavior, potentiation, psychotherapy.
Complement your search
- Click on the button below to complement your study and see how bacteria affect human behavior.
- Click on the button below to complement your study and see How microbes can mess up your head